This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: T27.1 (burn involving larynx and trachea with lung) | Special Copayment Reduction: V250 (special copayment reduction for severe burns, category 4: burns of the airway and digestive tract; 5% copayment for 1 year from the registration date) |
| B. Synonyms | Whole-airway inhalation injury, pulmonary parenchymal inhalation injury, Combined upper and lower airway inhalation injury, Smoke inhalation with pulmonary involvement |
| C. Adult onset | The most severe form of inhalation injury, involving both the upper and lower airways, occurring with prolonged smoke inhalation in an enclosed-space fire or inhalation of irritant chemical gases. The incidence of ARDS is high. |
| 1. History | With the development of critical care for severe burns in the 1960s~80s, the pathophysiology of inhalation injury involving the lungs and mechanical ventilation strategies were systematized. |
| 2. Causes | Prolonged smoke inhalation in an enclosed space, massive inhalation of chemical gases (phosgene, chlorine, ammonia, sulfur dioxide), combined CO and HCN toxicity |
| 3. Genetics | Polymorphisms in genes related to ARDS susceptibility (IL-6, TNF-α, ACE) influence the severity of lung injury |
| 4. General epidemiology | ARDS develops in about 20% of patients with inhalation injury; mortality of inhalation injury involving the lungs is reported to exceed 60% |
| 5. Pathophysiology | Chemical irritants reach the lower airways, causing bronchial mucosal injury, alveolar epithelial injury and acute lung injury (ALI)/ARDS |
| 6. Symptoms | Wheezing, dyspnea, tachypnea, hypoxemia, carbonaceous sputum, symptoms of pulmonary edema, symptoms of combined CO and HCN toxicity |
| 7. Signs | Auscultation: widespread crackles and wheezing; hypoxemia, hypercapnia, bilateral infiltrates on chest X-ray, lower airway injury on bronchoscopy |
| 8. Screening | ABGA, COHb, lactate, chest X-ray, bronchoscopy, PaO2/FiO2 ratio (ALI/ARDS criteria) |
| 9. Diagnosis | Bronchoscopy (confirming lower airway injury), chest CT, ABGA, application of the Berlin ARDS definition criteria |
| 10. Treatment | Lung-protective ventilation, nebulized heparin/NAC, PEEP optimization, prone positioning, HFOV or ECMO if needed, rescue therapy |
| 11. Prognosis | Mortality increases greatly when ARDS is present; survivors may develop chronic lung disease, airway stenosis and reduced lung function |
| 12. Prevention | Wearing SCBA, early fire detection systems, chemical emergency evacuation drills, staying low while escaping |
| 13. References | Mlcak RP et al. "Respiratory management of inhalation injury" Burns 2007 … and 9 other papers |
Inhalation injury involving the lung (T27.1) is the most severe form, in which chemical injury extends beyond the laryngeal and tracheal injury of T27.0 to the lower airways (bronchi, bronchioles) and alveoli. During the Vietnam War in the 1960s, extensive lung injury was observed in napalm burn patients, and the association between inhalation injury and pulmonary complications was studied in military medicine. Acute respiratory distress syndrome (ARDS), first described by Ashbaugh et al. (1967), came to be increasingly recognized as an important complication of burn inhalation injury as well.
In the 1980s, large clinical studies including the ARDSNet studies established evidence that a lung-protective ventilation strategy (low tidal volume ventilation, 6mL/kg IBW) lowers ARDS mortality. Nebulized heparin and N-acetylcysteine protocols for inhalation injury patients were first reported in the study by Desai et al. (1998) and were subsequently adopted by many institutions. With the introduction of high-frequency oscillatory ventilation (HFOV) and extracorporeal membrane oxygenation (ECMO) as rescue therapies, the chances of survival for patients with severe inhalation injury involving the lung have improved.
T27.1 arises from the same causes as the upper airway inhalation injury of T27.0, but the injury has spread to the lower airways (bronchi, alveoli). The main cause is massive inhalation of irritant chemical gases; phosgene, chlorine, ammonia and sulfur dioxide (SO2) penetrate to the lower airways and cause alveolar injury. In prolonged smoke inhalation in an enclosed space, irritants such as acrolein and aldehydes reach the lower airways and damage the alveolar epithelium. Combined high-concentration CO·HCN poisoning causes pulmonary parenchymal injury together with systemic cellular hypoxia.
Genetic predisposition is involved in the occurrence and severity of ARDS in inhalation injury involving the lung. A specific polymorphism (-174 G/C) of the IL-6 gene has been reported to be associated with the risk of developing ARDS. An insertion/deletion polymorphism of the ACE (angiotensin-converting enzyme) gene is related to ALI/ARDS susceptibility, and the D allele is associated with more severe lung injury. A TNF-α gene promoter polymorphism (-308 G/A) is associated with excessive TNF-α production and may influence the development of ARDS. Polymorphisms of the SFTPA1 and SFTPD genes, encoding surfactant proteins A and D, are also known to be involved in susceptibility to lung injury.
ARDS develops in about 20% of patients with inhalation injury, and inhalation injury involving the lung (T27.1) is one of the most severe clinical conditions in the burn ICU. Mortality in patients with both burns and inhalation injury is much higher than with burns alone (mortality about 10~15%) or inhalation injury alone (about 5~8%). Reported mortality in severe inhalation injury involving the lung exceeds 60% in some studies, and it varies greatly with age, burn area and the extent of lung injury. Cluster cases are reported in industrial accidents (chemical plant accidents, mining accidents) and large building fires.
When chemical irritants pass the glottis and reach the lower airways, injury to the bronchial mucosal epithelium occurs, and inflammatory mediators (histamine, leukotrienes, prostaglandins) are released, causing bronchospasm and mucosal edema. At the alveolar level, injury to type II pneumocytes reduces surfactant production, leading to alveolar collapse. Capillary endothelial injury allows protein-rich exudate to accumulate in the alveoli, producing noncardiogenic pulmonary edema. All of these processes lead to ventilation-perfusion mismatch (V/Q mismatch), increased intrapulmonary shunt and hypoxemia, forming the pathology of ARDS. Fibrin casts and carbon particles occlude the bronchioles, adding segmental atelectasis.
In inhalation injury involving the lung, symptoms from lower airway and lung involvement are added to the upper airway symptoms of T27.0. Severe dyspnea and progressive hypoxemia are characteristic, and pulse oxygen saturation (SpO2) falls rapidly. Copious carbonaceous sputum or blood-tinged sputum is present. Chest tightness, chest pain and severe cough appear. As pulmonary edema progresses, pink frothy sputum may appear. Combined CO and HCN toxicity symptoms (headache, dizziness, clouded consciousness, seizures) accompany it. Progression to respiratory failure can lead to loss of consciousness and cardiac arrest.
On physical examination, as signs of lung involvement, widespread crackles and wheezes are heard on chest auscultation. Tachypnea (>30 breaths/min), use of accessory respiratory muscles and cyanosis are observed. Pulse oximetry shows a rapid fall in SpO2. Dullness due to pulmonary edema may be noted on chest percussion. Hemodynamically, tachycardia and hypotension accompany it, suggesting hypoxemia and septic shock. Bronchoscopy shows mucosal erythema, eschar, fibrin casts and carbon deposition in the lower airways.
Arterial blood gas analysis (ABGA) shows decreased PaO2, increased or initially decreased PaCO2, and pH changes. A PaO2/FiO2 ratio (P/F ratio) below 300 meets the diagnostic criteria for ALI, and below 200 for ARDS (Berlin definition). Combined CO·HCN toxicity is assessed by measuring COHb and lactate. Chest X-ray shows bilateral lung field infiltrates. PaO2 is measured at 100% FiO2 to assess the pulmonary oxygen response. Lower airway injury grade is assessed by bronchoscopy.
Diagnosis of T27.1 requires evidence of lower airway and lung involvement in addition to the diagnostic criteria for T27.0 upper airway inhalation injury. If bronchoscopy shows mucosal injury in the lower airways (below the tracheal bifurcation), it is classified as T27.1. Chest CT assesses the extent of pulmonary parenchymal injury (ground-glass opacity, alveolar infiltrates, pulmonary edema). ARDS is confirmed by applying the Berlin ARDS diagnostic criteria (acute onset, bilateral lung opacities, exclusion of cardiogenic pulmonary edema, P/F ratio<300). Serum biomarkers (procalcitonin, CRP, IL-6) are used as an adjunct in differentiating it from infectious pneumonia.
Immediate endotracheal intubation and mechanical ventilation are essential. A lung-protective ventilation strategy (tidal volume 6mL/kg IBW, peak airway pressure <30cmH2O, titrated PEEP) is followed. When ARDS develops, prone positioning (16 hours or more/day) improves oxygenation and reduces mortality (PROSEVA trial). If oxygenation cannot be maintained with conventional ventilation strategies, high-frequency oscillatory ventilation (HFOV) or inhaled nitric oxide (inhaled NO) is used as rescue therapy.
A protocol of alternating nebulization of nebulized heparin (5,000~10,000 units, every 4 hours) and N-acetylcysteine (20% solution, 3mL, every 4 hours) is applied. Nebulized albuterol relieves bronchospasm. Fibrin casts are removed by regular bronchoscopic lavage.
If life-threatening hypoxemia persists despite mechanical ventilation (P/F <80), veno-venous ECMO (VV-ECMO) is performed as rescue therapy. Successful cases of ECMO have also been reported in burn inhalation injury patients, but the risk of bleeding complications must be considered.
T27.1 is one of the categories with the poorest prognosis among burns and inhalation injuries. When ARDS is present, mortality rises above 60% if severe burns coexist. Even survivors may develop long-term complications such as chronic lung disease (restrictive/obstructive pattern), airway stenosis, reduced exercise capacity and recurrent pneumonia. Recovery of lung function takes 6 months~2 years, and some are left with permanent loss of lung function. Post-traumatic stress disorder (PTSD) and post-intensive care syndrome (Post-ICU syndrome) also affect long-term prognosis.
To prevent serious inhalation injury involving the lung, a positive-pressure self-contained breathing apparatus (SCBA) must be worn when entering enclosed spaces. Facilities handling chemicals should install leak detectors for lung-toxic gases such as phosgene, chlorine and ammonia and establish an immediate evacuation system. During a building fire, escaping in a low posture can reduce inhalation of smoke and toxic gases. Training on the toxic properties of chemicals (IDLH concentration, first aid) is essential before hazardous work.
Mlcak RP, Suman OE, Herndon DN. Respiratory management of inhalation injury. Burns. 2007;33(1):2-13. DOI: 10.1016/j.burns.2006.09.012. PMID: 17222512.
The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301-1308. DOI: 10.1056/NEJM200005043421801. PMID: 10793162.
Guérin C, Reignier J, Richard JC, et al.; PROSEVA Study Group. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368(23):2159-2168. DOI: 10.1056/NEJMoa1214103. PMID: 23688302.
Enkhbaatar P, Traber DL. Pathophysiology of acute lung injury in combined burn and smoke inhalation injury. Clin Sci (Lond). 2004;107(2):137-143. DOI: 10.1042/CS20040135. PMID: 15132443.
Desai MH, Mlcak R, Richardson J, Nichols R, Herndon DN. Reduction in mortality in pediatric patients with inhalation injury with aerosolized heparin/N-acetylcystine therapy. J Burn Care Rehabil. 1998;19(3):210-212. DOI: 10.1097/00004630-199805000-00004. PMID: 9622463.
Rehberg S, Maybauer MO, Enkhbaatar P, Maybauer DM, Yamamoto Y, Traber DL. Pathophysiology, management and treatment of smoke inhalation injury. Expert Rev Respir Med. 2009;3(3):283-297. DOI: 10.1586/ers.09.17. PMID: 20477289.
Hampson NB, Piantadosi CA, Thom SR, Weaver LK. Practice recommendations in the diagnosis, management, and prevention of carbon monoxide poisoning. Am J Respir Crit Care Med. 2012;186(11):1095-1101. DOI: 10.1164/rccm.201207-1284CI. PMID: 22955317.
Reper P, Van Loey N. Inhalation injury: pathophysiology and management. J Plast Reconstr Aesthet Surg. 2009;62(7):871-878.
Chung KK, Wolf SE, Renz EM, et al. High-frequency percussive ventilation and low tidal volume ventilation in burns: a randomized controlled trial. Crit Care Med. 2010;38(10):1970-1977. DOI: 10.1097/CCM.0b013e3181eb3a0f. PMID: 20639753.
Cancio LC. Airway management and smoke inhalation injury in the burn patient. Clin Plast Surg. 2009;36(4):555-567. DOI: 10.1016/j.cps.2009.05.013. PMID: 19793550.